EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Efficacy of gut microbiota-targeted therapies in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials

Xiang Gu, Jihong Tang, Chanxi Chen

Frontiers in Cellular and Infection Microbiology · 25.09.2025 · 15

DOI: 10.3389/fcimb.2025.1627406 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 25.09.2025. Verfasst von Xiang Gu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Integrated Diagnosis and Treatment Center for Neurological Diseases, Yubei District People's Hospital of Chongqing, Chongqing, China. Hauptthemen laut MEDLINE: Parkinson Disease, Gastrointestinal Microbiome. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to investigate the efficacy of gut microbiota (GM)-targeted therapies in treating Parkinson’s disease (PD).

Methods

Randomized controlled trials (RCTs) were retrieved from PubMed, Embase, Cochrane, and WOS from database inception to June 2025. The eligible RCTs employed GM-targeted therapies, including antibiotics, probiotics, synbiotics, or fecal microbiota transplantation (FMT), as adjunct treatments for PD. Data were pooled using a random-effects model, and the effect sizes were expressed as standardized mean differences (SMDs). In addition, the quality of evidence for all outcomes was assessed using the GRADE framework.

Results

This study demonstrated that GM-targeted therapies significantly improved PD outcomes, including Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) III (SMD: -0.34, 95%CI: -0.57 to -0.11, P = 0.004), bowel movements (BMs) (SMD: 1.27, 95%CI: 0.35 to 2.2), use of laxatives (SMD: -0.33, 95% CI: -0.65 to -0.02), malondialdehyde (MDA) (SMD: -0.69, 95%CI: -1.23 to -0.15) indicators. However, there were no significant improvements in MDS-UPDRS I (SMD: -0.64, 95%CI: -1.42 to 0.13), MDS-UPDRS II (SMD: -0.28, 95%CI: -0.70 to 0.14), MDS-UPDRS IV (SMD: -0.08, 95% CI: -0.82 to 0.66), Mini-Mental State Examination (MMSE) (SMD: -0.01, 95% CI: -0.30 to 0.29), Montreal Cognitive Assessment (MoCA) (SMD: 0.04, 95%CI: -0.53 to 0.60), non-motor symptom scale (NMSS) (SMD: -0.11, 95%CI: -0.94 to 0.72), Parkinson’s Disease Questionnaire-39 (PDQ-39) (SMD: -0.19, 95%CI: -0.58 to 0.20), total antioxidant capacity (TAC) (SMD: 0.29, 95%CI: -0.04 to 0.62), glutathione (GSH) (SMD: 0.51, 95%CI: -0.02 to 1.03), and Geriatric Depression Scale-15 (GDS-15) (SMD: -0.37, 95%CI: -0.87 to 0.12).

Conclusion

GM-targeted therapies may improve motor symptom scores (as measured by MDS-UPDRS III), alleviate constipation, and reduce blood malondialdehyde levels in PD patients. However, they did not significantly impact the scores for cognitive function, PD neuropsychiatric, behavioral, and emotional symptoms, and activities of daily living in this analysis. Given the inherent limitations of the included studies (such as small sample sizes and heterogeneity), future large-scale and rigorously designed RCTs are needed to validate these preliminary findings. Systematic review registration https://www.crd.york.ac.uk/prospero/ , identifier CRD42024606415.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseGastrointestinal MicrobiomeHumansRandomized Controlled Trials as TopicFecal Microbiota TransplantationProbioticsTreatment OutcomeAnti-Bacterial AgentsSynbiotics

Stichwörter der Autor:innen

Parkinson’s diseaseantibioticsfecal microbiota transplantationmeta-analysisprobioticssynbiotics

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Integrated Diagnosis and Treatment Center for Neurological Diseases, Yubei District People's Hospital of Chongqing, Chongqing, China.
  • Department of Respiratory and Critical Care Medicine, Yubei District People's Hospital of Chongqing, Chongqing, China.

Zitieren

APA

Gu, X., Tang, J., & Chen, C. (2025). Efficacy of gut microbiota-targeted therapies in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Cellular and Infection Microbiology, 15. https://doi.org/10.3389/fcimb.2025.1627406

Vancouver

Gu X, Tang J, Chen C. Efficacy of gut microbiota-targeted therapies in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Cellular and Infection Microbiology. 2025;15. doi:10.3389/fcimb.2025.1627406

BibTeX
@article{Gu2025,
  author = {Gu, Xiang and Tang, Jihong and Chen, Chanxi},
  title = {Efficacy of gut microbiota-targeted therapies in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2025},
  volume = {15},
  doi = {10.3389/fcimb.2025.1627406}
}
Kostenlos starten →